Biogen
NEWS
When it comes to large-cap biotech companies, Gilead Sciences, Biogen and Celgene are always worth investment consideration, but are not without their risks.
The FDA issued two Complete Response Letters (CRLs) to South Korean manufacturer Celltrion. Teva Pharmaceutical Industries signed a deal in 2016 with Celltrion to commercialize the two biosimilars.
U.S. sales of AbbVie’s blockbuster Humira is safe from a biosimilar challenge from Samsung Bioepis, a joint project between Samsung and Biogen, until 2023.
If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
Novartis filed a federal lawsuit against a former executive, Alisha Alaimo. The lawsuit alleged that Alaimo stole confidential files using a flash drive before joining Biogen.
Yesterday’s news that Takeda Pharmaceuticals was considering acquiring Shire is raising the possibility of a bidding war. But it’s also having decidedly different effects on the two companies’ stock prices.
Here are six biotech companies that should benefit the most from research-and-development spending trends that are expected to stimulate biotech development.
Ionis Pharmaceuticals has signed a worldwide license deal to Akcea Therapeutics for inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion.
Foghorn Therapeutics has officially launched with a $50 million investment and the ambitious goal of altering the way our genes work.
JOBS
IN THE PRESS